Entourage Health Launches New Premium Color Cannabis Products

Includes Ontario launch of specialty concentrate product “Pedro’s Sweet Sativa Live Sugar”; debut of high-THC, rare cultivar “Space Cake”; and “Black Sugar Rose 10-pack Pre-rolls”

Toronto, Canada, January 27, 2022 – Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) (“Entourage” or the “Company”), a Canadian producer and distributor of award-winning cannabis products and brands is pleased to announce the expansion of its Color Cannabis adult-use lineup with the launch of three new premium products now available in Ontario, with expected expansion across Canada throughout the first quarter of 2022. 

New specialty concentrate: Crafted from Entourage’s award-winning cultivar, ‘Pedro's Sweet Sativa Live Sugar’ is a 77% to 83% THC live resin cannabis concentrate that is hydrocarbon extracted from fresh frozen flower to produce a sugar-in-honey consistency extract. Processed at the Company’s Aylmer facility, it represents the latest expansion into new cannabis offerings.

New pre-roll product: Terpene-rich cultivar ‘Black Sugar Rose’ debuts its 18% to 24% THC 10x0.35g pre-roll pack, which is gently milled directly from whole flower and conveniently packaged for single-session use. This is the latest Color cultivar added to the family of pre-roll products now available.

New small-batch cultivar: ‘Space Cake’, a 20% to 26% THC indica-dominant hybrid available in a 3.5g whole-flower format is a rare cross between cultivars Girl Scout Cookies and Snow Lotus. With its terpene-rich notes of musk and creamy diesel cues, Space Cake is small-batch-cultivated at Entourage’s Strathroy facility. This is the first in a series of commercially viable new cultivars coming in 2022.

“Following the recent enhancements to our cultivation programs and success of our in-house growing trials, we are excited to confirm we are broadening into the premium cannabis market with new flower and product formats drawn from our extensive genetics bank of higher potency, terpene-rich cultivars,” said George Scorsis, Interim CEO and Executive Chair. “Ensuring we are aligned with consumer preferences for innovative and consistent product flows will be key to the steady growth and success of our adult-use products under Color, Saturday and recent craft addition, Royal City Cannabis. Our portfolio has been carefully curated and the result is a lineup of whole flower, pre-rolls and concentrates garnering accolades across Canada. With our newest additions from Color, we expect to continue strengthening our portfolio with favoured products throughout 2022 as we launch additional cultivars and products nationwide.”

Recent retail data shows that Entourage experienced major growth in the premium flower and pre-roll market segments in 2021, representing a 535% sales increase over the prior year, with a 2.1% market share (Ref: Hifyre Data as of Dec. 31, 2021, published Jan. 2022). Additionally, its Color Cannabis brand was a top 10 performer in terms of retail growth in 2021 up 66% from the prior year (Ref: Buddi Data, Jan 5, 2022), representing growing consumer market share.  

Also in late 2021, the Company’s craft brand Royal City Cannabis Co. launched ‘RC Mango Haze Iced Hash’, and ‘RC Moonfire Crescent Hash’ processed at Entourage’s solventless specialty facility in Guelph, ON; its Saturday Cannabis brand debuted ‘Sweet & Sour Sativa Ready-to-Roll’ milled flower as well as vapes in ‘Blood Orange’ and ‘Watermelon’ flavours; and Color Cannabis released vapes in ‘Mango Haze Live Resin’ and ‘Black Sugar Rose Live Resin’. All vapes are processed in-house at Entourage’s extraction facility in Aylmer, ON.

To read Entourage’s recent Shareholder Newsletter 2022, visit our website here. To access our corporate video, visit us here and to access our latest investor presentation and corporate deck here


About Entourage Health Corp.

Entourage Health Corp. (formerly WeedMD Inc.) is the publicly traded parent company of Entourage Brands Corp. (formerly WeedMD RX Inc.) and CannTx Life Sciences Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, ON as well as a fully licensed 26,000 sq. ft. Aylmer, ON processing facility, specializing in cannabis extraction. With the addition of Starseed Medicinal, a medical-centric brand, Entourage has expanded its multi-channeled distribution strategy. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with employers and union groups complements Entourage’s direct sales to medical patients. In 2021, Entourage acquired craft cultivator CannTx Life Sciences Inc. which operates out of its state-of-the-art micropropagation and specialty extraction facility in Guelph, Ontario. Entourage’s elite adult-use product portfolio includes craft brand Royal City Cannabis, Color Cannabis and Saturday Cannabis – sold across eight provincial distribution agencies. The Company also maintains strategic relationships in the seniors’ market and supply agreements with Shoppers Drug Mart. It is the exclusive Canadian producer and distributor of award-winning U.S.-based wellness brand Mary’s Medicinals sold in both medical and adult-use channels. Entourage recently announced an exclusive collaboration with The Boston Beer Company subsidiary to launch cannabis-infused beverages in Canada. 

Follow Entourage and its brands on LinkedIn

Twitter: Entourage, Color Cannabis, Saturday Cannabis, Starseed & Royal City Cannabis Co.

Instagram: Entourage, Color Cannabis, Saturday Cannabis, Starseed & Royal City Cannabis Co.  

For further information, please contact:

For Investor Enquiries:
Valter Pinto
Managing Director 
KCSA Strategic Communications
1-212-896-1254
entourage@kcsa.com

For Media Enquiries:
Marianella delaBarrera
SVP, Communications & Corporate Affairs
416-897-6644
marianella@entouragecorp.com

Forward Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon Entourage's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information included in this press release includes, but is not limited to, statements in respect of the Company’s anticipated achievement of profitability.

The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of Entourage to implement its business strategies; the COVID-19 pandemic; competition; crop failure; and other risks.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Entourage does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Entourage to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in Entourage’s disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.


NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

Previous
Previous

Entourage Health Announces Preliminary Fiscal Year 2021 Record Revenue of $54.8 Million with Q4 and Full-Year 2021 Financials to be filed by April 1, 2022

Next
Next

Entourage Health Posts New Year 2022 Shareholder Newsletter